Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Clinical News

CVT-510: Began Phase II trial

March 27, 2000 8:00 AM UTC

CV Therapeutics Inc. (CVTX), Palo Alto, Calif. Product: CVT-510 Business: Cardiovascular Therapeutic category: Receptor agonist Target: Adenosine A1 receptors Description: Selective adenosine A1 rece...